乳腺癌组织中Ang-2及VEGF的表达及意义

目的研究乳腺癌组织中血管生成素(Ang-2)和血管内皮细胞生长因子(VEGF)的表达及临床意义。方法采用免疫组织化学SABC法,检测85例乳腺癌及42例乳腺纤维腺瘤组织中Ang-2及VEGF的表达情况,并评价两指标与乳腺癌临床病理学因素之间的关系。结果乳腺癌组织中Ang-2阳性率(68.24%,58/85)明显高于乳腺纤维腺瘤(7.14%,3/42)(P<0.0001),乳腺癌组织中VEGF阳性率(57.65%,49/85)也明显高于乳腺纤维腺瘤(4.76%,2/42)(P<0.0001)。Ang-2和VEGF表达与患者年龄及肿瘤大小无明显关系(P>0.05)。Ⅲ、Ⅳ期乳腺癌和淋巴结转移阳性组的VEGF表达阳性率明显高于Ⅰ、Ⅱ期乳腺癌和淋巴结转移阴性组(P<0.0001)。Ⅲ、Ⅳ期乳腺癌组的Ang-2表达阳性率高于Ⅰ、Ⅱ期乳腺癌组(P=0.015)。淋巴结转移阳性组的Ang-2阳性率明显高于淋巴结转移阴性组(P<0.0001)。Ang-2和VEGF两指标的表达具有相关性(P<0.05)。结论乳腺癌组织中Ang-2及VEGF有异常表达,与乳腺癌的预后有关。

Expression and Significance of Ang-2 and VEGF in Breast Carcinoma

Objective To investigate the expression and clinical significance of Ang-2 and VEGF in human breast carcinoma.Methods The expression of Ang-2 and VEGF in 85 specimens of breast carcinoma and in 42 specimens of fibroadenoma of breast was examined by SABC immunohistochemical method,and the relationship between these two factors and the clinicopathological factors was evaluated.Results The positive rate of Ang-2 in breast carcinoma(68.24%,58/85) was significantly higher than that in fibroadenoma of breast(7.14% , 3/ 42 ) ( P < 0. 0001 ) , and the positive rate of VEGF in breast carcinoma(57. 65 % ,49/ 85) was significantly higher than that in fibroadenoma of breast ( 4. 76 % , 2/ 42 ) ( P <0. 0001) ,too. The expression of Ang22 and VEGF were not associated with patient age and tumor size ( P> 0. 05) . The positive rate of VEGF in group of stage Ⅲand Ⅳ and lymph node2positive were signifi2cantly higher than that in group of stage Ⅰand Ⅱ and lymph node2negative respectively ( P < 0. 0001) .The positive rate of Ang22 in group of stage Ⅲand Ⅳwas significantly higher than that in group of stageⅠand Ⅱ ( P = 0. 015) . The positive rate of Ang22 in group of lymph node2positive was significantlyhigher than that in group of lymph node2negative ( P < 0. 0001) . There was a significantly correlation be2tween the expression of Ang22 and VEGF. Conclusion 　There was an abnormal expression of Ang22 andVEGF in breast carcinoma , these two factors were associated with the prognosis of patient s.